Thiogenesis Therapeutics, Corp.
TTIPFDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TTI-0102 | Phase 2 | MELAS Syndrome | - | - |
Frequently asked questions
What is in Thiogenesis Therapeutics, Corp.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Thiogenesis Therapeutics, Corp.'s (TTIPF) pipeline across Phase 2. Its lead program is TTI-0102 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Thiogenesis Therapeutics, Corp.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Thiogenesis Therapeutics, Corp. (TTIPF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track TTIPF biotech catalysts?→
Add TTIPF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Thiogenesis Therapeutics, Corp.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.